Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) – Equities research analysts at Zacks Research lowered their Q3 2023 earnings per share estimates for Axsome Therapeutics in a research note issued to investors on Monday, August 21st. Zacks Research analyst K. Shah now anticipates that the company will earn ($1.31) per share for the quarter, down […]
Axsome Therapeutics (NASDAQ:AXSM – Free Report) had its target price lifted by Mizuho from $95.00 to $100.00 in a research report released on Friday morning, MarketBeat Ratings reports. They currently have a buy rating on the stock. Several other research analysts also recently weighed in on AXSM. HC Wainwright dropped their target price on shares […]
Axsome Therapeutics (NASDAQ:AXSM – Free Report) had its price target lowered by HC Wainwright from $190.00 to $180.00 in a research report released on Tuesday, Marketbeat reports. The firm currently has a buy rating on the stock. HC Wainwright also issued estimates for Axsome Therapeutics’ Q3 2023 earnings at ($1.12) EPS, Q4 2023 earnings at […]
William Blair reiterated their outperform rating on shares of Axsome Therapeutics (NASDAQ:AXSM – Free Report) in a research note issued to investors on Monday morning, RTT News reports. A number of other analysts have also issued reports on the company. Mizuho boosted their price target on Axsome Therapeutics from $84.00 to $95.00 in a report […]
Envestnet Asset Management Inc. reduced its stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) by 12.9% in the 1st quarter, HoldingsChannel.com reports. The fund owned 10,473 shares of the company’s stock after selling 1,548 shares during the quarter. Envestnet Asset Management Inc.’s holdings in Axsome Therapeutics were worth $646,000 at the end […]